New hope for advanced cervical cancer: experimental drug SYS6002 faces chemo in major trial
NCT ID NCT07230626
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether the experimental drug SYS6002 works better than standard chemotherapy for people with recurrent or metastatic cervical cancer that has not responded to platinum chemo and immunotherapy. About 412 adults aged 18-75 will be randomly assigned to receive either SYS6002 or a chemo chosen by their doctor. The main goal is to see if SYS6002 helps people live longer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment